HealthcareServices

In-vitro Colorectal Cancer Screening Tests Market Forecast 2025–2034: Where Businesses Should Invest Next

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The In-vitro Colorectal Cancer Screening Tests Market By 2029?

The in-vitro colorectal cancer screening tests market has experienced significant expansion in recent years. Its valuation is predicted to climb from $1.21 billion in 2024 to $1.30 billion in 2025, registering a compound annual growth rate (CAGR) of 7.4%. This historical growth can be attributed to several factors, including increasing awareness of early cancer detection, a rise in government screening programs, increasing adoption of non-invasive testing methods, growing healthcare expenditure, and increasing availability of at-home screening kits.

The market size for in-vitro colorectal cancer screening tests is anticipated to experience robust expansion over the next few years. It is projected to reach $1.71 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period stems from various factors such as a heightened focus on personalized medicine, an increasing demand for economical diagnostic solutions, growing investments in cancer research, the rising adoption of molecular diagnostic techniques, the increasing incidence of colorectal cancer, and enhanced accessibility of testing in emerging markets. Significant trends expected in the forecast period include progress in liquid biopsy technologies, advancements in biomarker discovery, the integration of artificial intelligence into test analysis, sophisticated development of multi-target stool deoxyribonucleic acid tests, innovations in sample collection and processing, improvements in automation and digital pathology, and the incorporation of cloud-based diagnostic platforms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27319&type=smp

Which Drivers Are Shaping The In-vitro Colorectal Cancer Screening Tests Industry’s Market Share?

A projected increase in the incidence of colorectal cancer is anticipated to fuel the expansion of the in vitro colorectal cancer screening tests market in the coming years. This form of cancer originates in the colon or rectum, frequently developing from polyps that are precancerous. This growing occurrence is linked to detrimental lifestyle choices, given that an unhealthy diet, insufficient physical activity, and excess weight elevate the likelihood of polyp formation and subsequent cancer development. In-vitro colorectal cancer screening tests contribute to its diagnosis by providing non-invasive techniques for identifying early cancer indicators. These tests boost screening precision through advanced biomarker identification, which in turn facilitates prompt intervention and better patient prognoses. As an illustration, the American Cancer Society, a US-based nonprofit entity, reported an estimated 154,270 new colorectal cancer cases in February 2025, marking an ascent from 152,810 cases recorded in 2024. Consequently, the increasing prevalence of colorectal cancer is propelling the growth of the in vitro colorectal cancer screening tests market.

Which Key Segments Fueling The In-vitro Colorectal Cancer Screening Tests Market?

The in-vitro colorectal cancer screening tests market covered in this report is segmented

1) By Test Type: Fecal Occult Blood Test, Stool Deoxyribonucleic Acid Test, Blood Biomarker Test, Other Test Types

2) By Imaging Type: Colonoscopy, Proctoscopy, Computed Tomography Scan, Ultrasound, Magnetic Resonance Imaging, Positron Emission Tomography Scan

3) By Application: Screening, Diagnosis, Monitoring, Risk Assessment, Post-Treatment Surveillance

4) By End User: Hospitals, Diagnostic Laboratories, Outpatient Clinics, Home Care Settings, Research Institutions

Subsegments:

1) By Fecal Occult Blood Test: Guaiac Based Fecal Occult Blood Test, Immunochemical Fecal Occult Blood Test

2) By Stool Deoxyribonucleic Acid Test: Single Target Stool Deoxyribonucleic Acid Test, Multi Target Stool Deoxyribonucleic Acid Test

3) By Blood Biomarker Test: Methylated Septin 9 Deoxyribonucleic Acid Test, Circulating Tumor Deoxyribonucleic Acid Test, Protein Biomarker Based Blood Test

4) By Other Test Types: Urine Based Biomarker Test, Serum Based Biomarker Test, Breath Based Volatile Organic Compound Test

Which Trends Are Impacting The In-vitro Colorectal Cancer Screening Tests Market?

Major companies operating in the in vitro colorectal cancer screening tests market are concentrating on developing sophisticated diagnostic solutions, such as multi-target stool DNA tests, to elevate early detection accuracy, enhance patient convenience, and reduce colorectal cancer mortality rates. Multi-target stool DNA tests are innovative screening instruments that examine stool samples for genetic and biochemical markers associated with colorectal cancer and precancerous lesions. For instance, in March 2025, Exact Sciences Corp., a US-based molecular diagnostics company, introduced Cologuard Plus, an improved at-home colorectal cancer screening test for average-risk adults aged 45 and older. This test incorporates advanced biomarker technology, providing higher sensitivity and specificity compared to its predecessor. It utilizes a refined algorithm to detect DNA mutations and hemoglobin biomarkers, thereby enhancing the detection of both colorectal cancer and advanced adenomas. The Cologuard Plus test offers a non-invasive and convenient screening option that eliminates the need for bowel preparation or dietary restrictions, consequently increasing patient adherence to recommended screening guidelines.

Which Key Players Are Driving Competition In The In-vitro Colorectal Cancer Screening Tests Market?

Major companies operating in the in-vitro colorectal cancer screening tests market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Quest Diagnostics Incorporated, Roche Diagnostics International AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Natera Inc., Leica Biosystems Nussloch GmbH, BGI Genomics Co. Ltd., NeoGenomics Inc., Guardant Health Inc., CellMax Life Inc., Epigenomics AG, Acuamark Diagnostics Inc., Beacon Biomedical Inc., Mainz Biomed NV.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/in-vitro-colorectal-cancer-screening-tests-global-market-report

How Do Regional Market Performances Compare Within The In-vitro Colorectal Cancer Screening Tests Industry?

North America was the largest region in the in-vitro colorectal cancer screening tests market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro colorectal cancer screening tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The In-vitro Colorectal Cancer Screening Tests Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27319&type=smp

Browse Through More Reports Similar to the Global In-vitro Colorectal Cancer Screening Tests Market 2025, By The Business Research Company

Buildings Construction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/buildings-construction-global-market-report

Residential Building Construction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/residential-building-construction-global-market-report

Construction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795